Intra-Cellular Therapies' high P/S ratio may signal investor...
Intra-Cellular Therapies' high P/S ratio may signal investor hope for strong revenue, though analysts show less confidence. Their high valuation could face significant risk due to the disparity between the P/S ratio and revenue predictions.
Unpleasant Surprises Could Be In Store For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Shares
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment